东富龙(300171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300171 东富龙

已收盘 01-13 15:00:00

{"stockData":{"symbol":"300171","market":"SZ","secType":"STK","nameCN":"东富龙","latestPrice":17.78,"timestamp":1768287828000,"preClose":17.98,"halted":0,"volume":27264646,"delay":0,"changeRate":-0.0111,"floatShares":563000000,"shares":766000000,"eps":0.2258,"marketStatus":"已收盘","change":-0.2,"latestTime":"01-13 15:00:00","open":17.93,"high":18.5,"low":17.59,"amount":491000000,"amplitude":0.0506,"askPrice":17.79,"askSize":40,"bidPrice":17.78,"bidSize":288,"shortable":0,"etf":0,"ttmEps":0.2258,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":17.98,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":19.78,"lowLimit":16.18,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":765828040,"isCdr":false,"pbRate":1.75,"roa":"--","peRate":78.74225,"roe":"1.68%","epsLYR":0.26,"committee":-0.054893,"marketValue":13616000000,"turnoverRate":0.0485,"status":1,"floatMarketCap":10004000000},"requestUrl":"/m/hq/s/300171","defaultTab":"news","newsList":[{"id":"2602939166","title":"股市必读：东富龙（300171）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602939166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602939166?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:16","pubTimestamp":1767892573,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，东富龙报收于17.03元，上涨2.1%，换手率2.32%，成交量13.07万手，成交额2.21亿元。董秘最新回复投资者： 公司持有上海诺诚电气多少股份董秘： 您好，截至目前，公司未持有上海诺诚电器股份，感谢您的关注！当日关注点来自交易信息汇总：1月8日主力资金净流入1775.8万元，显示主力对东富龙股票的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2601833831","title":"东富龙：坚守专业技术服务于生物医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2601833831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601833831?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:45","pubTimestamp":1767833113,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙(300171)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的企业文化是什么？可以详细的解说一下吗？谢谢东富龙回复：您好，公司及全体员工秉承“天道酬勤、诚信、敬业、创新、学习”的价值观，坚守专业技术服务于生物医药，致力于成为智慧药厂的交付者。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800006160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0251","161726","300171"],"gpt_icon":0},{"id":"2601487839","title":"股市必读：东富龙（300171）1月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601487839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601487839?lang=zh_cn&edition=full","pubTime":"2026-01-06 02:11","pubTimestamp":1767636669,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，东富龙报收于16.64元，上涨5.99%，换手率2.74%，成交量15.44万手，成交额2.53亿元。董秘最新回复投资者： 公司参股了哪些生物医药公司？当日关注点来自交易信息汇总：1月5日主力资金净流入1659.23万元，显示主力对东富龙的积极布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600001115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2601001034","title":"东富龙：提升产品差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2601001034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601001034?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:54","pubTimestamp":1767603259,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙(300171)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司毛利净利率太差了，这样下去生存都困难！东富龙回复：您好，公司积极立足“提质增效”的主题，发挥产品创新的技术优势，提升公司产品结合前沿技术的能力，进一步打造产品的差异化竞争优势，做好为客户提供泛服务的能力，为赢取优质订单奠定扎实基础，努力提升公司的盈利能力。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500023189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2600067979","title":"每周股票复盘：东富龙（300171）开展2025年度持续督导培训","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067979?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:51","pubTimestamp":1767379868,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，东富龙报收于15.7元，较上周的15.94元下跌1.51%。本周，东富龙12月29日盘中最高价报16.07元。12月31日盘中最低价报15.6元。东富龙当前最新总市值120.24亿元，在医疗器械板块市值排名23/127，在两市A股市值排名1623/5181。本周关注点公司公告汇总：东富龙于2025年12月22日接受中信证券开展的持续督导培训。公司对本次培训积极配合，中信证券认为培训达到了预期效果，有助于提升公司规范运作水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2595795602","title":"东富龙（300171）披露2025年度持续督导培训情况，12月30日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595795602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595795602?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:55","pubTimestamp":1767088547,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，东富龙报收于15.78元，较前一交易日下跌0.94%，最新总市值为120.85亿元。该股当日开盘15.86元，最高15.97元，最低15.78元，成交额达7329.02万元，换手率为0.82%。公司近日发布公告称，中信证券股份有限公司于2025年12月22日在上海市闵行区都会路1509号对东富龙科技集团股份有限公司开展了2025年度持续督导培训。公司对本次培训积极配合，中信证券认为培训达到了预期效果，有助于提升公司规范运作水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2593049851","title":"东富龙：可提供药品制造核心装备整体解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2593049851","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593049851?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:25","pubTimestamp":1766478330,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙(300171)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司能为药企一个新建的厂房提供里面所有需要的装备设备吗？或只提供一部分？希望能认真回答我，谢谢！东富龙回复：您好，根据客户的需求，公司可以为客户定制化提供制药工艺、核心装备、系统工程整体解决方案，产品能涵盖药品制造过程中所需要的核心装备。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2593460028","title":"东富龙：募投项目实施进度有所放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2593460028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593460028?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:21","pubTimestamp":1766478077,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙12月23日在投资者关系平台上答复投资者关心的问题。去年不是推迟一次了吗？行业下行周期还要多久才能到底？公司一直没有机构调研，到底怎么回事？公司将实时关注募投项目的实施进展，加强对项目实施过程中的动态控制，结合市场变化情况及公司经营发展需要，制定实施计划，合理统筹，有序推进募投项目后续建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300022578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2592160716","title":"东富龙（300171）披露部分募投项目延期公告，12月19日股价上涨0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592160716?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:18","pubTimestamp":1766153916,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，东富龙报收于15.37元，较前一交易日上涨0.92%，最新总市值为117.71亿元。该股当日开盘15.24元，最高15.46元，最低15.24元，成交额达8681.32万元，换手率为1.0%。东富龙近日发布公告称，公司于2025年12月19日召开董事会，审议通过关于部分募投项目延期的议案。其中，生物制药装备产业试制中心项目延期至2027年3月24日，江苏生物医药装备产业化基地项目延期至2027年1月10日，浙江东富龙生命科学产业化基地项目延期至2027年7月15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2591609329","title":"东富龙：子公司专注洁净药厂建设工程服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2591609329","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591609329?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:21","pubTimestamp":1765869685,"startTime":"0","endTime":"0","summary":"东富龙回复：您好，公司全资子公司上海东富龙德惠空调设备有限公司、上海东富龙德惠净化空调工程安装有限公司秉承专业技术服务于生物医药的使命，专门从事洁净空调设备研发与生产、洁净药厂建设工程服务，专注于高端制药领域，如抗肿瘤原料药和抗肿瘤制剂、生物原液和生物制剂，服务了上百家国内外医药企业，积累了大量的项目经验，可以为新老客户提供更优质的服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600019726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2591609553","title":"东富龙：国际业务收入8.05亿元占营收33.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591609553","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591609553?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:21","pubTimestamp":1765869684,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙12月16日在投资者关系平台上答复投资者关心的问题。公司国际化程度怎样？2025年半年度报告期内，公司实现国际业务收入8.05亿元，占公司报告期营业收入33.14%，较上年同期增长63.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600019725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171"],"gpt_icon":0},{"id":"2588366884","title":"东富龙：提升行业影响力和市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588366884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588366884?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:48","pubTimestamp":1764852494,"startTime":"0","endTime":"0","summary":"投资者提问：东富龙国内的竞争对手太多，太强。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2588965083","title":"港股异动 | 维升药业-B(02561)再涨超12% 隆培促生长素即将获批 公司近期与东富龙达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2588965083","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588965083?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:04","pubTimestamp":1764644686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B(02561)再涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82万港元。消息面上，安科生物近期披露合作进展，与维升药业合作的隆培促生长素即将获批。据悉，7月14日，安科生物宣布，公司与维升药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及。值得注意的是，11月6日，第八届进博会期间，维升药业与国内制药装备龙头企业东富龙达成双腔冻干制剂技术战略合作，并与临港新片区管委会、临港集团物贸平台签署产业协同协议，标志着其在“全球创新、中国加速”的战略实践进一步落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","BK1161","300171","02561"],"gpt_icon":0},{"id":"2585452860","title":"东富龙：提升经营业绩回报投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452860?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973043,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙11月24日在投资者关系平台上答复投资者关心的问题。我是一个普通投资者，我买东富龙近四年了，成本价34元，请问何时会有投资回报？请郑总给我们东富龙投资人一个答复！未来公司将继续努力提升公司经营业绩，积极采取规则允许的市值管理手段，实现公司内在价值与市场价值的平衡来回报所有投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2583110575","title":"11月14日东富龙涨6.93%，金信深圳成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583110575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583110575?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:36","pubTimestamp":1763109401,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日东富龙涨6.93%创60日新高，收盘报18.2元，换手率7.08%，成交量39.85万手，成交额7.23亿元。重仓东富龙的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为金信基金的金信深圳成长混合A。金信深圳成长混合A目前规模为2.67亿元，最新净值2.8609，较上一交易日上涨0.77%，近一年上涨40.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2582180932","title":"股市必读：东富龙（300171）11月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582180932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582180932?lang=zh_cn&edition=full","pubTime":"2025-11-11 01:37","pubTimestamp":1762796231,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，东富龙报收于16.99元，上涨0.18%，换手率2.44%，成交量13.74万手，成交额2.33亿元。董秘最新回复投资者： 公司会增资国家战投资金吗？单靠卖设备的制造业是很难让公司变强大的！感谢您的关注及建议。当日关注点来自交易信息汇总：11月10日主力资金净流出872.61万元，显示主力短期谨慎态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100000629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2580788988","title":"11月4日东富龙跌5.11%，金信深圳成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788988?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:32","pubTimestamp":1762245126,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日东富龙跌5.11%，收盘报17.07元，换手率5.45%，成交量30.69万手，成交额5.28亿元。融资融券方面近5日融资净流入1457.9万，融资余额增加；融券净流出1400.0，融券余额减少。重仓东富龙的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为金信基金的金信深圳成长混合A。金信深圳成长混合A目前规模为2.67亿元，最新净值2.883，较上一交易日下跌0.25%，近一年上涨58.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171","BK0251"],"gpt_icon":0},{"id":"2579171862","title":"股市必读：东富龙（300171）10月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579171862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579171862?lang=zh_cn&edition=full","pubTime":"2025-10-31 03:49","pubTimestamp":1761853773,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，东富龙报收于16.84元，下跌1.81%，换手率5.0%，成交量28.14万手，成交额4.76亿元。公司将根据行业及市场环境的变化情况，合理推进募投项目的建设与投产工作。当日关注点来自交易信息汇总：10月30日主力资金净流出2508.76万元，散户资金净流入4195.99万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100006061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300171"],"gpt_icon":0},{"id":"2579419601","title":"东富龙：制药装备行业竞争激烈","url":"https://stock-news.laohu8.com/highlight/detail?id=2579419601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579419601?lang=zh_cn&edition=full","pubTime":"2025-10-30 15:36","pubTimestamp":1761809775,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙10月30日在投资者关系平台上答复投资者关心的问题。当前，国内外制药装备行业竞争依然激烈，公司坚持通过自主创新和战略实施提升自身市场竞争力，为客户提供满意的产品及整体解决方案，赢得客户的信任从而获取更多的优质订单。公司将根据行业及市场环境的变化情况，合理推进募投项目的建设与投产工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000024493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1191","BK1574","300171","BK0251"],"gpt_icon":0},{"id":"2579995294","title":"股市必读：东富龙三季报 - 第三季度单季净利润同比增长120.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579995294","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579995294?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:18","pubTimestamp":1761679123,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2025年9月30日，东富龙股东户数环比下降2.14%，户均持股数量上升至2.44万股。股本股东变化股东户数变动截至2025年9月30日，东富龙股东户数为3.14万户，较6月30日减少688.0户，减幅为2.14%；户均持股数量由上期的2.39万股增至2.44万股，户均持股市值为34.74万元。业绩披露要点财务报告东富龙2025年三季报显示，公司主营收入37.04亿元，同比上升6.14%；归母净利润1.32亿元，同比下降13.86%；扣非净利润1.05亿元，同比下降20.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300171"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768292422538,"stockEarnings":[{"period":"1week","weight":0.0805},{"period":"1month","weight":0.1767},{"period":"3month","weight":0.2512},{"period":"6month","weight":0.3507},{"period":"1year","weight":0.5011},{"period":"ytd","weight":0.1452}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"东富龙科技集团股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"31415人(较上一季度减少2.14%)","perCapita":"17910股","listingDate":"2011-02-01","address":"上海市闵行区都会路1509号4幢","registeredCapital":"76582万元","survey":"　　东富龙科技集团股份有限公司的主营业务是为全球制药企业提供制药工艺、核心装备、系统工程整体解决方案。公司的主要产品是液态食品前处理线，食品冻干系统，液体灌装线及无菌灌装线等包装设备。","listedPrice":86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东富龙(300171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东富龙(300171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东富龙,300171,东富龙股票,东富龙股票老虎,东富龙股票老虎国际,东富龙行情,东富龙股票行情,东富龙股价,东富龙股市,东富龙股票价格,东富龙股票交易,东富龙股票购买,东富龙股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东富龙(300171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东富龙(300171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}